Indivior Plc, a global pharmaceutical corporation, confirmed on Thursday that its subsidiary, Indivior Inc., had successfully obtained final court approval for its settlement with the Direct Purchaser class, effectively ending the long-standing anti-trust multi-district litigation issue.
On October 22, 2023, Indivior Inc. had reached an agreement with the remaining representatives of the Direct Purchaser class, agreeing to a settlement amount of $385 million. This settlement was approved by the United States District Court for the Eastern District of Pennsylvania, who officially dismissed the Direct Purchaser class claims on February 27, 2024, by issuing the final judgment and order of dismissal. Consequently, this move marked the conclusion of the Antitrust multi-district litigation.
